# Association between the expression of specific microRNAs and prostate cancer progression- a systematic review and meta-analysis

**Authors:** Jihad Awadallah Alrehaili

PMC · DOI: 10.3389/fonc.2024.1481885 · Frontiers in Oncology · 2025-02-07

## TL;DR

This study reviews how specific microRNAs are linked to prostate cancer progression and their potential as biomarkers.

## Contribution

The paper provides a meta-analysis of miRNA expression in prostate cancer, highlighting their role in proliferation and metastasis prediction.

## Key findings

- MiRNAs significantly reduce prostate cancer proliferation with an odds ratio of 0.28 and risk ratio of 0.51.
- MiRNAs show significant predictive value for metastasis with a pooled odds ratio of 0.60 and risk ratio of 0.72.
- Moderate heterogeneity was observed in proliferation studies, but low in metastasis prediction studies.

## Abstract

This systematic review and metanalysis aimed to summarize the evidence supporting the significance of particular MiRNAs in PrCa progression and to thoroughly examine the body of prior research.

In accordance with the PRISMA guidelines, this review was conducted using a specifically design data extraction protocol and searching several online databases for relevant articles. The protocol was registered in the PROSPERO database (CRD42023428460).

8 studies were ultimately included in this review. MiRNAs significantly reduced PrCa proliferation, with an odds ratio (OR) of 0.28 (95% CI: 0.21–0.39) and a risk ratio (RR) of 0.51 (95% CI: 0.43–0.61), though moderate heterogeneity was observed (I² = 57%). For two studies investigating MiRNAs as biomarkers for predicting metastasis, the pooled OR was 0.60 (95% CI: 0.47–0.76) and the RR was 0.72 (95% CI: 0.62–0.84), both demonstrating significant predictive value with low heterogeneity (I² = 0%).

The results emphasize the potential of miRNAs as biomarkers for predicting PrCa metastasis and demonstrate that miRNAs have a discernible effect on PrCa proliferation. However, to improve our comprehension of MiRNA’s function in this condition, additional studies are required to address the limitations and investigate how MiRNA acts in many areas of PrCa.

https://www.crd.york.ac.uk/prospero/, identifier CRD42023428460.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Diseases:** PrCa metastasis (MESH:D009362), prostate cancer (MESH:D011471)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11842264/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11842264/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC11842264/full.md

---
Source: https://tomesphere.com/paper/PMC11842264